Abstract
Introduction
The pharmacokinetics and safety of Asacol® (Tillotts Pharma AG, Ziefen, Switzerland), which has been used worldwide to treat ulcerative colitis and Crohn’s disease, were studied in Japanese healthy male volunteers.
Methods
Drug plasma concentrations and urinary and fecal excretions after a single dose (400–4800 mg) and multiple doses (3600 mg/day for 7 days) were investigated.
Results
All adverse events were “not serious.” The peak plasma concentration (Cmax) was reached at 12.3–18.0 hours after a single dose, and the Cmax and area under the plasma concentration-time curve (AUC) of mesalazine and its N-acetyl metabolite were proportional to the doses. The Cmax and AUC in non-Japanese subjects reported in the literature were closely correlated to findings in Japanese subjects, and external excretions were also similar in the Japanese and non-Japanese subjects.
Conclusions
Asacol was safe and well tolerated in this Japanese population, and the non-Japanese clinical data could be extrapolated to the Japanese population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J. 2004;80:206–213.
Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.
Andoh A, Yagi Y, Shioya M, et al. Mucosal cytokine network in inflam-matory bowel disease. World J Gastroenterol. 2008;14:5154–5161.
Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001;7:221–225.
Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47:410–414.
Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200.
Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350–355.
Moshkovska T, Mayberry JF. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol. 2007;13:4310–4315.
De Vos M, Verdievel H, Schoonjans R, et al. High-performance liquid chromatographic assay for the determination of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid concentrations in endoscopic intestinal biopsy in humans. J Chromatogr. 1991;564:296–302.
Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine: Rockville, MD. Available at: www.fda.gov/CVM. Accessed May 2009.
Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004;19:1089–1098.
Corey AE, Rose GM, Conklin JD. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. J Int Med Res. 1990;18:441–453.
Rijk MC, van Schaik A, van Tongeren JH. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol Suppl. 1988;148:54–59.
Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-amino-salicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990;31:1271–1276.
Mardini HA, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987;28:1084–1089.
Pharmaceutical and Medical Safety Bureau. Ministry of Health and Welfare notification of directors of bureaus, Yakuhatsu No. 739. Ethnic factors in the acceptability of foreign clinical data. August 11, 1998. Available at: www.pmda.go.jp/ich/e/e5_98_8_11.pdf. Accessed May 2009.
Higaki H, Nakayama S, Tanaka Y, et al. Phase I clinical study of oral controlled-release mesalazine, N-5ASA: single dose study. Japan Pharmacol Ther. 1994;22(suppl. 10):5–33.
Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron. 1994;67:481–482.
Fukino K, Sasaki Y, Hirai S, et al. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-Stransferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci. 2008;33:187–195.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ito, H., Furuta, S., Sasaki, H. et al. Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. Adv Therapy 26, 749–761 (2009). https://doi.org/10.1007/s12325-009-0059-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-009-0059-9